Safety of live attenuated influenza vaccine in mild to moderately immunocompromised children with cancer

Vaccine

Volumn 29, Issue 24, 2011, Pages 4110-4115

  Halasa, Natasha ^a   Englund, Janet A ^b   Nachman, Sharon ^c   Weinberg, Geoffrey A ^d   Huber, Victor C ^e   Allison, Kim ^f   Dubovsky, Filip ^g   Yi, Tingting ^g   McCullers, Jonathan A ^f   Flynn, Patricia M ^f  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b SEATTLE CHILDREN S HOSPITAL   (United States)

^c STONY BROOK UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTH DAKOTA   (United States)

^f ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^g MEDIMMUNE   (United States)

Author keywords

Cancer; Influenza; Live attenuated influenza vaccine; Randomized trial

Indexed keywords

BUFFER; INFLUENZA VACCINE; LIVE VACCINE;

ADOLESCENT; AGED; ARTICLE; BLOOD; CHILD; CHILL; CLINICAL ARTICLE; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FATIGUE; FEMALE; FEVER; HEADACHE; HEMAGGLUTINATION INHIBITION; HEMATOLOGIC DISEASE; HUMAN; IMMUNOASSAY; IMMUNOCOMPROMISED PATIENT; IMMUNOGENICITY; INCIDENCE; IRRITABILITY; MALE; MULTICENTER STUDY; NEOPLASM; NONHUMAN; NOSE CONGESTION; NOSE SMEAR; PRESCHOOL CHILD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SCHOOL CHILD; SIDE EFFECT; SOLID TUMOR; SORE THROAT; VACCINATION; VIRUS NEUTRALIZATION; VIRUS SHEDDING; VOMITING;

ADMINISTRATION, INTRANASAL; ADOLESCENT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; DOUBLE-BLIND METHOD; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; IMMUNOCOMPROMISED HOST; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; NASAL MUCOSA; NEOPLASMS; PLACEBOS; VACCINES, ATTENUATED; VIRUS SHEDDING;

EID: 79956104763     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.03.097     Document Type: Article

References (43)

1. Glezen W.P. Influenza and hospitalizations in children. N Engl J Med 2000, 342:1752-1753.
2. Glezen W.P., Greenberg S.B., Atmar R.L., Piedra P.A., Couch R.B. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA 2000, 283:499-505.
3. Poehling K.A., Edwards K.M., Weinberg G.A., Szilagyi P., Staat M.A., Iwane M.K., et al. The underrecognized burden of influenza in young children. N Engl J Med 2006, 355:31-40.
4. Neuzil K.M., Coffey C.S., Mitchel E.F., Griffin M.R. Cardiopulmonary hospitalizations during influenza season in adults and adolescents with advanced HIV infection. J Acquir Immune Defic Syndr 2003, 34:304-307.
5. Neuzil K.M., Mellen B.G., Wright P.F., Mitchel E.F., Griffin M.R. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med 2000, 342:225-231.
6. Neuzil K.M., Wright P.F., Mitchel E.F., Griffin M.R. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000, 137:856-864.
7. Neuzil K.M., Zhu Y., Griffin M.R., Edwards K.M., Thompson J.M., Tollefson S.J., et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis 2002, 185:147-152.
8. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342:232-239.
9. Feldman S., Webster R.G., Sugg M. Influenza in children and young adults with cancer: 20 cases. Cancer 1977, 39:350-353.
10. Tasian S.K., Park J.R., Martin E.T., Englund J.A. Influenza-associated morbidity in children with cancer. Pediatr Blood Cancer 2008, 50:983-987.
11. Allison J.E., Glezen W.P., Taber L.H., Paredes A., Webster R.G. Reactogenicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high-risk children. J Infect Dis 1977, 136:S672-S676.
12. Goossen G.M., Kremer L.C., van de Wetering M.D. Influenza vaccination in children being treated with chemotherapy for cancer. Cochrane Database Syst Rev 2009, CD006484.
13. Porter C.C., Edwards K.M., Zhu Y., Frangoul H. Immune responses to influenza immunization in children receiving maintenance chemotherapy for acute lymphoblastic leukemia. Pediatr Blood Cancer 2004, 42:36-40.
14. Matsuzaki A., Suminoe A., Koga Y., Kinukawa N., Kusuhara K., Hara T. Immune response after influenza vaccination in children with cancer. Pediatr Blood Cancer 2005, 45:831-837.
15. Kempe A., Hall C.B., MacDonald N.E., Foye H.R., Woodin K.A., Cohen H.J., et al. Influenza in children with cancer. J Pediatr 1989, 115:33-39.
16. Influenza virus vaccine live intranasal-MedImmune vaccines: CAIV-T, influenza vaccine live intranasal. Drugs R D 2003, 4:312-319.
17. Fiore A.E., Shay D.K., Broder K., Iskander J.K., Uyeki T.M., Mootrey G., et al. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009, 58:1-52.
18. Mears C.J., Lawler E.N., Sanders L.D., Katz B.Z. Efficacy of LAIV-T on absentee rates in a school-based health center sample. J Adolesc Health 2009, 45:91-94.
19. Eick A.A., Wang Z., Hughes H., Ford S.M., Tobler S.K. Comparison of the trivalent live attenuated vs. inactivated influenza vaccines among U.S. military service members. Vaccine 2009, 27:3568-3575.
20. Belshe R.B., Edwards K.M., Vesikari T., Black S.V., Walker R.E., Hultquist M., et al. Live attenuated versus inactivated influenza vaccine in infants and young children. N Engl J Med 2007, 356:685-696.
21. Tosh P.K., Boyce T.G., Poland G.A. Flu myths: dispelling the myths associated with live attenuated influenza vaccine. Mayo Clin Proc 2008, 83:77-84.
22. King J.C., Fast P.E., Zangwill K.M., Weinberg G.A., Wolff M., Yan L., et al. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J 2001, 20:1124-1131.
23. King J.C., Treanor J., Fast P.E., Wolff M., Yan L., Iacuzio D., et al. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis 2000, 181:725-728.
24. Levin M.J., Song L.Y., Fenton T., Nachman S., Patterson J., Walker R., et al. Shedding of live vaccine virus, comparative safety, and influenza-specific antibody responses after administration of live attenuated and inactivated trivalent influenza vaccines to HIV-infected children. Vaccine 2008, 26:4210-4217.
25. Huber V.C., Kleimeyer L.H., McCullers J.A. Live, attenuated influenza virus (LAIV) vehicles are strong inducers of immunity toward influenza B virus. Vaccine 2008, 26:5381-5388.
26. Hoffmann E., Mahmood K., Yang C.F., Webster R.G., Greenberg H.B., Kemble G. Rescue of influenza B virus from eight plasmids. Proc Natl Acad Sci U S A 2002, 99:11411-11416.
27. Hoffmann E., Neumann G., Kawaoka Y., Hobom G., Webster R.G. A DNA transfection system for generation of influenza A virus from eight plasmids. Proc Natl Acad Sci U S A 2000, 97:6108-6113.
28. Huber V.C., Thomas P.G., McCullers J.A. A multi-valent vaccine approach that elicits broad immunity within an influenza subtype. Vaccine 2009, 27:1192-1200.
29. Huber V.C., McCullers J.A. Live attenuated influenza vaccine is safe and immunogenic in immunocompromised ferrets. J Infect Dis 2006, 193:677-684.
30. Rowe T., Abernathy R.A., Hu-Primmer J., Thompson W.W., Lu X., Lim W., et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
31. Vesikari T., Fleming D.M., Aristegui J.F., Vertruyen A., Ashkenazi S., Rappaport R., et al. Safety, efficacy, and effectiveness of cold-adapted influenza vaccine-trivalent against community-acquired, culture-confirmed influenza in young children attending day care. Pediatrics 2006, 118:2298-2312.
32. Edwards K.M., King J.C., Steinhoff M.C., Thompson J., Clements M.L., Wright P.F., et al. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991, 163:740-745.
33. Sears S.D., Clements M.L., Betts R.F., Maassab H.F., Murphy B.R., Snyder M.H. Comparison of live, attenuated H1N1 and H3N2 cold-adapted and avian-human influenza A reassortant viruses and inactivated virus vaccine in adults. J Infect Dis 1988, 158:1209-1219.
34. Anderson E.L., Newman F.K., Maassab H.F., Belshe R.B. Evaluation of a cold-adapted influenza B/Texas/84 reassortant virus (CRB-87) vaccine in young children. J Clin Microbiol 1992, 30:2230-2234.
35. Murphy B.R. Use of live attenuated cold-adapted influenza reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect Dis Clin Pract 1993, 2:174-181.
36. Englund J.A., Champlin R.E., Wyde P.R., Kantarjian H., Atmar R.L., Tarrand J., et al. Common emergence of amantadine- and rimantadine-resistant influenza A viruses in symptomatic immunocompromised adults. Clin Infect Dis 1998, 26:1418-1424.
37. Leekha S., Zitterkopf N.L., Espy M.J., Smith T.F., Thompson R.L., Sampathkumar P. Duration of influenza A virus shedding in hospitalized patients and implications for infection control. Infect Control Hosp Epidemiol 2007, 28:1071-1076.
38. Klimov A.I., Rocha E., Hayden F.G., Shult P.A., Roumillat L.F., Cox N.J. Prolonged shedding of amantadine-resistant influenzae A viruses by immunodeficient patients: detection by polymerase chain reaction-restriction analysis. J Infect Dis 1995, 172:1352-1355.
39. Block S.L., Reisinger K.S., Hultquist M., Walker R.E. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007, 51:4001-4008.
40. Edwards K.M., Dupont W.D., Westrich M.K., Plummer W.D., Palmer P.S., Wright P.F. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994, 169:68-76.
41. Treanor J.J., Kotloff K., Betts R.F., Belshe R., Newman F., Iacuzio D., et al. Evaluation of trivalent, live, cold-adapted (CAIV-T) and inactivated (TIV) influenza vaccines in prevention of virus infection and illness following challenge of adults with wild-type influenza A (H1N1), A (H3N2), and B viruses. Vaccine 1999, 18:899-906.
42. Hauge S.H., Dudman S., Borgen K., Lackenby A., Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-2008. Emerg Infect Dis 2009, 15:155-162.
43. Arino J., Bowman C.S., Moghadas S.M. Antiviral resistance during pandemic influenza: implications for stockpiling and drug use. BMC Infect Dis 2009, 9:8.